Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia

Fujishiro, Hiroshige; Iseki, Eizo; Higashi, Shinji; Kasanuki, Koji; Murayama, Norio; Togo, Takashi; Katsuse, Omi; Uchikado, Hirotake; Aoki, Naoya; Kosaka, Kenji; Arai, Heii; Satô, Kiyoshi

doi:10.1016/j.neulet.2010.09.036

Cited by 65 publications

(65 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amyloid deposits have been linked to cognitive impairment in DLB 44,45 and may contribute to the timing of the onset of dementia relative to that of Parkinsonism in Lewy body dementia. 46 However, as shown in Fig 6, severe metabolic reduction was seen in some patients with DLB despite no evidence of amyloid deposits. In particular, regional metabolic reduction in patients with DLB was observed in the parietotemporal, posterior cingulate, and frontal association cortices, which are the same regions affected in AD but are not correlated with amyloid deposit.…”

Section: Amyloid Imaging In Dementia With Lewy Bodiesmentioning

confidence: 81%

PET Approaches for Diagnosis of Dementia

Ishii

2013

AJNR Am J Neuroradiol

105

View full text Add to dashboard Cite

SUMMARY:There is increasing use of neuroimaging modalities, including PET, for diagnosing dementia. For example, FDG-PET demonstrates hypometabolic regions in the posterior cingulate gyri, precuneus, and parietotemporal association cortices, while amyloid PET indicates amyloid deposition in Alzheimer disease and mild cognitive impairment due to Alzheimer disease. Furthermore, the use of combination PET with structural MR imaging can improve the diagnostic accuracy of dementia. In other neurodegenerative dementias, each disease exhibits a specific metabolic reduction pattern. In dementia with Lewy bodies, occipital glucose metabolism is decreased, while in frontotemporal dementia, frontal and anterior temporal metabolism is predominantly decreased. These FDG-PET findings and positive or negative amyloid deposits are important biomarkers for various neurodegenerative dementias. ABBREVIATIONS:A␤ ϭ amyloid ␤ peptide; AD ϭ Alzheimer disease; APOE ϭ apolipoprotein E; CBD ϭ corticobasal degeneration; DLB ϭ dementia with Lewy

show abstract

Section: Amyloid Imaging In Dementia With Lewy Bodiesmentioning

confidence: 81%

PET Approaches for Diagnosis of Dementia

Ishii

2013

AJNR Am J Neuroradiol

105

View full text Add to dashboard Cite

show abstract

“…4,5 Coexisting Alzheimer disease (AD) pathology occurs in 51% to 66% of those with pathologically confirmed DLB. 1,6 Accurate antemortem prediction of underlying causes of dementia is important for determining a prognosis, 7,8 predicting treatment response, 9 and planning for clinical trials.…”

mentioning

confidence: 99%

Dementia with Lewy bodies

et al. 2014

View full text Add to dashboard Cite

Objectives: To investigate clinical, imaging, and pathologic associations of the cingulate island sign (CIS) in dementia with Lewy bodies (DLB).Methods: We retrospectively identified and compared patients with a clinical diagnosis of DLB (n 5 39); patients with Alzheimer disease (AD) matched by age, sex, and education (n 5 39); and cognitively normal controls (n 5 78) who underwent 18 F-fluorodeoxyglucose (FDG) and C11 Pittsburgh compound B (PiB)-PET scans. Among these patients, we studied those who came to autopsy and underwent Braak neurofibrillary tangle (NFT) staging (n 5 10). Dementia with Lewy bodies (DLB) is the second most common cause of dementia.1 Despite revised criteria, 2 clinically distinguishing DLB from other neurodegenerative diseases continues to be problematic. In fact, the National Alzheimer's Coordinating Center registry reported the sensitivity of clinical diagnoses of DLB compared with subsequent pathologic examination to be 32.1%. 3Complicating the inaccuracies of clinical diagnosis, the majority of dementia cases have multiple pathologies at autopsy. 4,5 Coexisting Alzheimer disease (AD) pathology occurs in 51% to 66% of those with pathologically confirmed DLB. 1,6 Accurate antemortem prediction of underlying causes of dementia is important for determining a prognosis, 7,8 predicting treatment response, 9 and planning for clinical trials. Additional biomarkers are required to better distinguish DLB from AD and to predict relative contributions of different underlying pathologies to DLB. By measuring b-amyloid (Ab) deposition with C11 Pittsburgh compound B (PiB) binding, investigators have demonstrated that more than half of patients with DLB have Ab deposition in the brain. 10,11From the Departments of Neurology

show abstract

“…Moreover, recent clinicopathological and neuroimaging studies reported that amyloid deposition contributes to the timing of the onset of dementia relative to that of parkinsonism in PD dementia and DLB. [10][11][12] This suggests the existence of a continuum between PD dementia and DLB in terms of the Lewy body disease's pathophysiological process. DLB patients likely have mood fluctuations, and the pharmacological approach to treating these symptoms in PD patients would also be useful for DLB patients.…”

Section: Discussionmentioning

confidence: 99%

Levodopa treatment and mood fluctuation in dementia with Lewy bodies: a case report

2013

Self Cite

View full text Add to dashboard Cite

L-3,4-dihydroxyphenylalanine (L-dopa) has been the gold standard for pharmacotherapy for parkinsonism in patients with dementia with Lewy bodies (DLB). While L-dopa treatment is related to visual hallucinations, its relationship to mood fluctuation in DLB is poorly understood. Herein, we report the improvement of behavioural and psychological symptoms of dementia through the adjustment of L-dopa treatment in a 78-year-old woman with probable DLB. Her marked mood swings were improved by changing L-dopa administration from three to five times per day while maintaining the same total daily dosage. This observation suggests that there may be an association between plasmatic L-dopa levels and mood fluctuation in patients with DLB. This pharmacological approach may be useful in the management of behavioural and psychological symptoms of dementia without the use of antipsychotic agents to avoid severe neuroleptic sensitivity, which is one of the suggestive clinical features in the Third Consortium on DLB clinical criteria.

show abstract

Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia

Cited by 65 publications

References 19 publications

PET Approaches for Diagnosis of Dementia

PET Approaches for Diagnosis of Dementia

Dementia with Lewy bodies

Levodopa treatment and mood fluctuation in dementia with Lewy bodies: a case report

Contact Info

Product

Resources

About